Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114444 | PMC |
| http://dx.doi.org/10.1164/rccm.201606-1159ED | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The study was outlined to develop and approve a nomogram and chance stratification demonstrate for foreseeing overall survival of Chinese patients with at first metastatic small-cell lung cancer (SCLC). We collected information from the Surveillance, Epidemiology, and End Results (SEER) database approximately Chinese SCLC patients with at first distant metastases between 2010 and 2015. Patients with incomplete data about the follow-up time or clinicopathological information were excluded.
View Article and Find Full Text PDFNeoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
J Clin Oncol
September 2024
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Purpose: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA -mutated non-small cell lung cancer (NSCLC).
Patients And Methods: This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) -mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469).
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
Alzheimers Dement
August 2024
Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Article Synopsis
- - The National Institute on Aging and Alzheimer's Association updated their 2018 framework for diagnosing Alzheimer's disease (AD) to align with new research and biological definitions of diseases, which apply to all neurodegenerative disorders.
- - The document outlines criteria for diagnosing and staging AD based on biomarkers, emphasizing that the disease begins biologically before symptoms appear and progresses as neuropathological changes worsen.
- - Core 1 biomarkers, like amyloid PET and specific cerebrospinal fluid markers, are critical for initial diagnosis, while Core 2 biomarkers help provide additional insights and prognostic information as the disease advances.
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.
J Crohns Colitis
November 2024
Human Pathobiology & OMNI Reverse Translation, Genentech, South San Francisco, CA, USA.
Background And Aims: The gut microbiota contributes to aberrant inflammation in inflammatory bowel disease, but the bacterial factors causing or exacerbating inflammation are not fully understood. Further, the predictive or prognostic value of gut microbial biomarkers for remission in response to biologic therapy is unclear.
Methods: We perform whole metagenomic sequencing of 550 stool samples from 287 ulcerative colitis patients from a large, phase 3, head-to-head study of infliximab and etrolizumab.
"Just the Facts Ma'am": Moral and Ethical Considerations for Artificial Intelligence in Medicine and its Potential to Impact Patient Autonomy and Hope.
Linacre Q
November 2023
Venture Sciences Group, LLC, Santa Barbara, CA, USA.
Applying machine-based learning and synthetic cognition, commonly referred to as artificial intelligence (AI), to medicine intimates prescient knowledge. The ability of these algorithms to potentially unlock secrets held within vast data sets makes them invaluable to healthcare. Complex computer algorithms are routinely used to enhance diagnoses in fields like oncology, cardiology, and neurology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!